<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="publisher-id">nss</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34785966</article-id>
      <article-id pub-id-type="pmc">8579875</article-id>
      <article-id pub-id-type="publisher-id">328348</article-id>
      <article-id pub-id-type="doi">10.2147/NSS.S328348</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Biomarkers and Dynamic Cerebral Autoregulation of Obstructive Sleep Apnea-Hypopnea Syndrome</article-title>
        <alt-title alt-title-type="running-authors">Zhang et al</alt-title>
        <alt-title alt-title-type="running-title">Zhang et al</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Yanan</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Xiaodan</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Qingqing</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Qi</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>Zhen-Ni</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Zan</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
          <xref rid="an0001" ref-type="corresp"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Yi</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref>
          <xref rid="an0002" ref-type="corresp"/>
        </contrib>
        <aff id="aff0001"><label>1</label><institution>Department of Neurology and Neuroscience Center, the First Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>People’s Republic of China</country></aff>
        <aff id="aff0002"><label>2</label><institution>Department of Neurology and Neuroscience Center, Clinical Trial and Research Center for Stroke, the First Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>People’s Republic of China</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="an0001">Correspondence: Zan Wang <institution>Department of Neurology and Neuroscience Center, the First Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>People’s Republic of China</country> Email wangzan@jlu.edu.cn; wangzanprof@163.com</corresp>
        <corresp id="an0002">Yi Yang <institution>Department of Neurology and Neuroscience Center, Clinical Trial and Research Center for Stroke, the First Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>People’s Republic of China</country> Email yang_yi@jlu.edu.cn; doctoryangyi@163.com</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>06</day>
        <month>11</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2021</year>
      </pub-date>
      <volume>13</volume>
      <fpage>2019</fpage>
      <lpage>2028</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>7</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>10</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2021 Zhang et al.</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>Zhang et al.</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref>
          <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <sec id="s2001">
          <title>Objective</title>
          <p><citation_analysis attribute="neither">Patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) have impaired dynamic cerebral autoregulation (dCA). This study aimed to explore whether serum levels of apolipoprotein B-100 (ApoB-100), fibronectin (FN), and ceruloplasmin (CP) were related to impaired dCA in OSAHS.</citation_analysis></p>
        </sec>
        <sec id="s2002">
          <title>Methods</title>
          <p><citation_analysis attribute="positive">A total of 90 patients with OSAHS from our database management system were enrolled and further divided into three subgroups according to the apnea-hypopnea index (AHI) using polysomnography results: mild (5 ≤ AHI ≤ 15), moderate (15 &lt; AHI ≤ 30), and severe OSAHS (AHI &gt; 30), with 30 patients in each group. Thirty sex- and age-matched healthy controls were recruited for this study. The serum levels of ApoB-100, FN, and CP were measured by enzyme-linked immunosorbent assays. dCA was assessed by analyzing the phase difference (PD) using transfer function analysis.</citation_analysis></p>
        </sec>
        <sec id="s2003">
          <title>Results</title>
          <p><citation_analysis attribute="neither">Serum levels of ApoB-100, FN, and CP were significantly higher in the mild, moderate, and severe OSAHS groups than that in the control group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.001, respectively). The average PD of the moderate and severe OSAHS groups was lower than that of the control group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">=0.001 and </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.001, respectively). Receiver operating curve analysis revealed that ApoB-100, FN, and CP might be able to distinguish patients with OSAHS from healthy individuals (area under the curve = 0.959 [95% CI 0.92–1.00], 0.987 [95% CI 0.96–1.01], 0.982 [95% CI 0.96–1.00]), respectively, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.001). The average PD was linearly correlated with the serum levels of ApoB-100, FN, and CP in patients with OSAHS. Multivariable analysis showed that FN and arousal index in polysomnography were associated with impaired average PD (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.001 and </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">=0.025, respectively).</citation_analysis></p>
        </sec>
        <sec id="s2004">
          <title>Conclusion</title>
          <p><citation_analysis attribute="neither">Serum levels of ApoB-100, FN, and CP increased in patients with OSAHS. dCA was compromised in patients with OSAHS and was positively correlated with ApoB-100, FN, and CP serum levels, and FN serum levels and arousal index in polysomnography were independently associated with impaired dCA.</citation_analysis></p>
        </sec>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords</title>
        <kwd>obstructive sleep apnea-hypopnea syndrome</kwd>
        <kwd>apolipoprotein B-100</kwd>
        <kwd>fibronectin</kwd>
        <kwd>ceruloplasmin</kwd>
        <kwd>dynamic cerebral autoregulation</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
<institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100001809</institution-id></institution-wrap>
</funding-source>
        </award-group>
        <award-group>
          <funding-source>
<institution-wrap><institution>the Foundation of the Department of Science and Technology of Jilin Province</institution></institution-wrap>
</funding-source>
        </award-group>
        <award-group>
          <funding-source>
<institution-wrap><institution>the Foundation of Chinese Sleep Research Society Hansoh Project</institution></institution-wrap>
</funding-source>
        </award-group>
        <funding-statement>The article was supported by the National Natural Science Foundation of China (Grant Number 82071489), the Foundation of the Department of Science and Technology of Jilin Province (Grant Number 20190201038JC), and the Foundation of Chinese Sleep Research Society Hansoh Project (Grant Number 2019HSB05) to ZW.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="9"/>
        <ref-count count="39"/>
        <page-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0001">
      <title>Introduction</title>
      <p><citation_analysis attribute="neither">Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a common disease characterized by a decrease or cessation of airflow due to repeated collapse and obstruction of the upper airway and results in recurrent oxyhemoglobin desaturation and sleep fragmentation,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> which triggers the development of systemic inflammation,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither"> oxidative stress,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0003" ref-type="bibr">3</xref></citation_analysis><citation_analysis attribute="neither"> endothelial dysfunction,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither"> and metabolic syndrome.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="neither"> Studies have found that dynamic cerebral autoregulation (dCA) is impaired in patients with OSAHS, which may play an important role in the predisposition to stroke in these patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither"> Cerebral autoregulation (CA) is the intrinsic ability of the brain to maintain adequate cerebral perfusion in the presence of blood pressure changes. dCA can respond to real-time changes in blood pressure within seconds, allowing continuous measurement of CA and wave-by-wave analysis of hemodynamics.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither"> The dCA mechanism is complex and includes myogenic, metabolic, endothelial, and neurogenic mechanisms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The diagnosis and severity of OSAHS is usually based on polysomnography (PSG), which is expensive and cumbersome.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> Therefore, it is important to identify predictive biomarkers of OSAHS.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="neither"> Studies have found that apolipoprotein B-100 (ApoB-100), fibronectin (FN), and ceruloplasmin (CP) are overexpressed in patients with OSAHS and correlate with the severity of disease.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="neither"> OSAHS could cause metabolic dysfunction and abnormal lipid metabolism; in such cases, the utilization rate of lipids decreases, resulting in an increase in plasma levels. ApoB-100 can induce macrophages to take in cholesterol and form foam cells, which can cause atherosclerosis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither"> In addition, hypoxia could promote the synthesis and secretion of FN in myofibroblasts in patients with OSAHS,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="neither"> and acute inflammation interferes with the normal degradation process of CP, resulting in increased serum levels of CP.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0013" ref-type="bibr">13</xref></citation_analysis><citation_analysis attribute="neither"> FN may affect platelet adhesion on fibrin and promote thrombosis indirectly.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0014" ref-type="bibr">14</xref></citation_analysis><citation_analysis attribute="positive"> CP is an acute inflammatory response protein, which could oxidize and deform low-density lipoprotein (LDL) and promote vascular lesions. The increasing serum levels of CP can result in atherosclerotic plaque rupture.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither"> ApoB-100, FN, and CP are related to several metabolic pathways, such as the lipid and vascular metabolic pathways,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="positive"> suggesting that they may facilitate the onset and progression of atherogenesis and likely affect dCA.</citation_analysis></p>
      <p><citation_analysis attribute="positive">In this study, we assessed dCA and the serum levels of ApoB-100, FN, and CP from patients with OSAHS and explored the relationship among dCA, serum marker, and OSAHS, providing more evidence for the evaluation and diagnosis of OSAHS.</citation_analysis></p>
    </sec>
    <sec id="s0002">
      <title>Methods</title>
      <p><citation_analysis attribute="positive">The study was approved by the ethics committee of the First Hospital of Jilin University in accordance with the guidelines of the Declaration of Helsinki (1964). All participants and guardians signed written informed consent forms.</citation_analysis></p>
      <sec id="s0002-s2001">
        <title>Participants</title>
        <p><citation_analysis attribute="neither">Patients with OSAHS who were already scheduled for PSG were recruited from the database management system of Department of Neurology, First Hospital of Jilin University, from March 2019 to March 2020. Patients were classified according to their apnea-hypopnea index (AHI) scores as mild (5 ≤ AHI ≤ 15), moderate (15 &lt; AHI ≤ 30), or severe (AHI &gt; 30). There were 90 OSAHS patients with good bilateral temporal window penetration from the database management system enrolled (30 with mild OSAHS, 30 with moderate OSAHS, and 30 with severe OSAHS). Thirty sex- and age-matched healthy controls were recruited from the same region according to their PSG results.</citation_analysis></p>
        <p><citation_analysis attribute="neither">The inclusion criteria for the different groups were as follows: (1) Control group: age- and sex-matched healthy volunteers without sleep disorder in PSG; (2) OSAHS groups: met the diagnostic criteria of mild, moderate, and severe OSAHS according to the International Classification of Sleep Disorders 3rd edition; (3) age between 18 and 65 years; and (4) good bilateral temporal window penetration (could detect cerebral hemispheric blood flow signal and spectrum through the temporal window for 10 minutes).</citation_analysis></p>
        <p><citation_analysis attribute="positive">The exclusion criteria included (1) combination of other sleep disorders except for OSAHS according to PSG; (2) epilepsy, psychiatric disorders, drug abuse, suspicion of anxiety [7-item Hamilton Anxiety Rating Scale &gt; 8] or depression [7-item Hamilton Depression Rating Scale &gt; 8]; (3) arrhythmia, hyperthyroidism, and other hemodynamic factors; (4) intracranial and extracranial vascular stenosis or occlusion diagnosed by vascular ultrasound; and (5) inability to cooperate with the questionnaire survey.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2002">
        <title>Collection of Clinical Data</title>
        <p><citation_analysis attribute="positive">Clinical evaluation included sex, age, medical history, neurological examination, and magnetic resonance imaging. Questionnaires were completed, and medical histories were obtained before the subjects underwent sleep studies. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS).</citation_analysis></p>
      </sec>
      <sec id="s0002-s2003">
        <title>Polysomnography</title>
        <p><citation_analysis attribute="positive">All subjects were monitored for at least 8 h at the sleep center of our hospital using PSG (Compumedics, Abbotsford, Australia). PSG results were analyzed by professional sleep technicians with PSG technologist certification by referring to the revised interpretation criteria of sleep stages and related events issued by the American Academy of Sleep Medicine version 2.3. Apnea was defined as a ≥90% decrease in airflow for more than 10s; hypopnea was defined as a ≥30% decrease in airflow for 10s associated with a decrease in oxygen saturation for ≥3%, or electroencephalogram arousal. AHI was defined as the number of apnea or hypopnea events per hour during sleep.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2004">
        <title>ApoB-100, FN, and CP Serum Level Detection</title>
        <p><citation_analysis attribute="positive">Blood samples and dCA from all participants were collected between 8:00–11:00 am. Serum samples were gauged using morning fasting venous blood samples and centrifuged at 3000 rpm for 10 min. The serum was stored at −20°C before further use. Enzyme-linked immunosorbent assays (ELISA; Enzyme Immunoassay Kit, Chi Mingrui Biological Technology Co., Ltd, Shanghai, China) were used to measure the serum levels of ApoB-100, FN, and CP.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2005">
        <title>Dynamic Cerebral Autoregulation Measurement and Analysis</title>
        <p><citation_analysis attribute="neither">Participants were instructed to avoid alcohol, nicotine, and caffeine intake and exercise for at least 12 h before the measurement. The measurements were performed in a quiet, dedicated laboratory. First, the subjects had their baseline arterial blood pressure (Omron 711; Omron, Kyoto, Japan) and heart rate (HR) measured.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="neither"> Then, beat-to-beat arterial blood pressure (Finometer Model 1; Finapres Medical Systems, Enschede, Netherlands) and continuous bilateral middle cerebral artery blood flow velocity (MultiDop X2; DWL, Sipplingen, Germany) were recorded spontaneously for 10 min. The measurement data were then stored for further dCA examination analysis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="neither"> End-tidal CO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="positive"> was monitored using a capnography with a facemask attached to the nasal cannula. All measurements were performed by an experienced operator.</citation_analysis></p>
        <p><citation_analysis attribute="positive">Recorded data were processed using MATLAB software (MathWorks, Natick, MA). dCA analysis was performed using transfer function analysis (TFA). TFA between the arterial blood pressure and cerebral blood flow velocity was calculated as the quotient of the cross-spectrum of the two signals and the auto-spectrum of arterial blood pressure in the low-frequency domain (0.06–0.12 Hz) to obtain the frequency-dependent estimates of phase difference (PD), where the derived parameters are considered to be the most relevant to autoregulation hemodynamics.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="neither"> A decreased PD represents impaired dCA. Coherence was calculated to estimate the reliability of the relationship between the two signals in the frequency domain, and statistical analysis was later performed only if the coherence of the parameters was &gt; 0.5.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis></p>
      </sec>
      <sec id="s0002-s2006">
        <title>Statistical Analysis</title>
        <p><citation_analysis attribute="neither">SPSS software (version 23.0; IBM, Armonk, NY) was used for statistical analysis. The Shapiro–Wilk test was used to assess the normal distribution of continuous variables. Data with a normal distribution (including age, body mass index [BMI], mean arterial blood pressure [MAP], HR, ESS, ApoB-100, FN, CP, PD, end-tidal CO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither"> [ETPCO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">], total sleep time [TST], sleep onset latency [SL], sleep efficiency [SE], rapid eye movement [REM], stage 1 non-REM [stage N1], stage 2 NREM [stage N2], stage 3 NREM [stage N3], arousal index, AHI, mean SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, minimum SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">) were expressed as mean and standard deviation, whereas data with skewed distribution were expressed as medians with interquartile range. Categorical data (sex, hypertension, and hyperlipidemia) were expressed as absolute values and percentages. One-way analysis of variance or the Kruskal–Wallis </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">H</italic></citation_analysis><citation_analysis attribute="neither">-test was used to compare differences between multiple groups of independent samples (age, BMI, MAP, HR, ESS, ApoB-100, FN, CP, PD, ETPCO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, TST, SL, SE, REM, stage N1, stage N2, stage N3, arousal index, AHI, mean SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, minimum SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="positive"> of mild, moderate, and severe OSAHS and control groups) based on the data distribution. Receiver operating characteristic (ROC) curves were used to determine the sensitivity, specificity, and cutoff point of ApoB-100, FN, and CP serum levels to predict OSAHS based on the Youden index. The correlation between PD and ApoB-100, FN, and CP serum levels was examined using the non-parametric Spearman correlation test. The correlation between ESS, sleep latency in PSG, and apoB-100, FN, and CP serum levels were examined using the non-parametric Spearman correlation test. Univariate and multivariate linear regression were used to assess the association between PD and clinical parameters including sex, age, BMI, MAP, HR, hypertension, hyperlipidemia, ETPCO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, ApoB-100, FN, CP, TST, SL, SE, arousal index, stage N1, stage N2, stage N3, REM, AHI, mean SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, and minimum SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="positive">. In the post-hoc analysis, the Bonferroni method was used to calculate the adjusted </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">-value. Statistical significance was set at </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05.</citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0003">
      <title>Results</title>
      <sec id="s0003-s2001">
        <title>Baseline Characteristics</title>
        <p><citation_analysis attribute="positive">A total of 120 participants were enrolled in this study, including 30 mild OSAHS patients, 30 moderate OSAHS patients, 30 severe OSAHS patients, and 30 controls. There were no significant differences in sex, age, MAP, HR, hypertension, hyperlipidemia, or ETPCO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither"> among the study groups. BMI was significantly higher in the severe OSAHS group compared to the control and mild OSAHS groups (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05). ESS scores in patients with mild, moderate, and severe OSAHS were significantly higher than those in the control group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001) (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="neither">). The PSG parameters of all groups are presented in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="neither">.</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0001"><label>Table 1</label><caption><p><citation_analysis attribute="neither">Clinical Characteristics, ApoB-100, FN, CP Serum Levels and Phase Difference in the Patients with Mild, Moderate, Severe OSAHS and Controls</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Controls (n = 30)</th><th rowspan="1" colspan="1">Mild OSAHS (n = 30)</th><th rowspan="1" colspan="1">Moderate OSAHS (n = 30)</th><th rowspan="1" colspan="1">Severe OSAHS (n = 30)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male, n (%)</td><td rowspan="1" colspan="1">21 (70.0)</td><td rowspan="1" colspan="1">18 (60.0)</td><td rowspan="1" colspan="1">22 (73.3)</td><td rowspan="1" colspan="1">24 (80.0)</td><td rowspan="1" colspan="1">0.388</td></tr><tr><td rowspan="1" colspan="1"> Age (years)</td><td rowspan="1" colspan="1">48.1 ± 10.4</td><td rowspan="1" colspan="1">48.3 ± 10.3</td><td rowspan="1" colspan="1">49.9 ± 11.7</td><td rowspan="1" colspan="1">49.3 ± 9.4</td><td rowspan="1" colspan="1">0.896</td></tr><tr><td rowspan="1" colspan="1"> BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">24.00 ± 3.43</td><td rowspan="1" colspan="1">24.47 ± 3.41</td><td rowspan="1" colspan="1">25.48 ± 2.45</td><td rowspan="1" colspan="1">26.54 ± 2.51</td><td align="center" rowspan="1" colspan="1">0.007 <sup>a</sup></td></tr><tr><td rowspan="1" colspan="1"> MAP (mmHg)</td><td rowspan="1" colspan="1">85.03 ± 14.90</td><td rowspan="1" colspan="1">84.23 ± 12.21</td><td rowspan="1" colspan="1">85.93 ± 11.30</td><td rowspan="1" colspan="1">86.77 ± 8.66</td><td rowspan="1" colspan="1">0.860</td></tr><tr><td rowspan="1" colspan="1">Heart Rate (beats/min)</td><td rowspan="1" colspan="1">65.1 ± 7.7</td><td rowspan="1" colspan="1">68.7 ± 8.7</td><td rowspan="1" colspan="1">66.6 ± 7.3</td><td rowspan="1" colspan="1">68.7 ± 8.6</td><td rowspan="1" colspan="1">0.238</td></tr><tr><td rowspan="1" colspan="1"> Hypertension, n (%)</td><td align="center" rowspan="1" colspan="1">4 (13.3)</td><td align="center" rowspan="1" colspan="1">6 (20.0)</td><td align="center" rowspan="1" colspan="1">8 (26.7)</td><td align="center" rowspan="1" colspan="1">8 (26.7)</td><td rowspan="1" colspan="1">0.540</td></tr><tr><td rowspan="1" colspan="1"> Hyperlipidemia, n (%)</td><td align="center" rowspan="1" colspan="1">5 (16.7)</td><td align="center" rowspan="1" colspan="1">6 (20.0)</td><td align="center" rowspan="1" colspan="1">9 (30.0)</td><td align="center" rowspan="1" colspan="1">7 (23.3)</td><td rowspan="1" colspan="1">0.643</td></tr><tr><td rowspan="1" colspan="1">Epworth sleepiness scale</td><td rowspan="1" colspan="1">2.4 ± 1.0</td><td rowspan="1" colspan="1">6.7 ± 3.8</td><td rowspan="1" colspan="1">11.9 ± 5.1</td><td rowspan="1" colspan="1">11.1 ± 5.0</td><td rowspan="1" colspan="1">&lt; 0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1"> ApoB-100 (g/L)</td><td rowspan="1" colspan="1">0.470 ± 0.093</td><td rowspan="1" colspan="1">1.515 ± 0.392</td><td rowspan="1" colspan="1">1.143 ± 0.204</td><td rowspan="1" colspan="1">0.947 ± 0.350</td><td rowspan="1" colspan="1">&lt; 0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1"> FN (g/L)</td><td rowspan="1" colspan="1">0.483 ± 0.109</td><td rowspan="1" colspan="1">1.629 ± 0.313</td><td rowspan="1" colspan="1">1.260 ± 0.240</td><td rowspan="1" colspan="1">1.098 ± 0.302</td><td rowspan="1" colspan="1">&lt; 0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1"> CP (g/L)</td><td rowspan="1" colspan="1">0.496 ± 0.127</td><td rowspan="1" colspan="1">1.665 ± 0.351</td><td rowspan="1" colspan="1">1.178 ± 0.276</td><td rowspan="1" colspan="1">1.032 ± 0.257</td><td rowspan="1" colspan="1">&lt; 0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Phase difference (degree)</td><td rowspan="1" colspan="1">52.37 ± 9.39</td><td rowspan="1" colspan="1">48.22 ± 12.27</td><td rowspan="1" colspan="1">39.05 ± 10.97</td><td rowspan="1" colspan="1">31.14 ± 17.45</td><td rowspan="1" colspan="1">&lt; 0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1"> End-tidal CO<sub>2</sub> (mmHg)</td><td rowspan="1" colspan="1">35.52 ± 2.52</td><td rowspan="1" colspan="1">35.41 ± 2.20</td><td rowspan="1" colspan="1">35.38 ± 3.14</td><td rowspan="1" colspan="1">35.72 ± 2.94</td><td rowspan="1" colspan="1">0.963</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><citation_analysis attribute="positive"><bold>Note</bold></citation_analysis><citation_analysis attribute="neither">: </citation_analysis><citation_analysis attribute="positive"><sup>a</sup></citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> value &lt; 0.05 (statistically different).</citation_analysis></p></fn><fn id="tfn0002"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="neither">: BMI, body mass index; MAP, mean arterial pressure; ApoB-100, apolipoprotein B-100; FN, fibronectin; CP, ceruloplasmin.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0002"><label>Table 2</label><caption><p><citation_analysis attribute="neither">Polysomnography Parameters in the Patients with Mild, Moderate, Severe OSAHS and Controls</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Controls (n = 30)</th><th rowspan="1" colspan="1">Mild OSAHS (n = 30)</th><th rowspan="1" colspan="1">Moderate OSAHS (n = 30)</th><th rowspan="1" colspan="1">Severe OSAHS (n = 30)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total Sleep Time (min)</td><td rowspan="1" colspan="1">390.40 ± 33.23</td><td rowspan="1" colspan="1">389.86 ± 45.97</td><td rowspan="1" colspan="1">386.14 ± 62.17</td><td rowspan="1" colspan="1">379.15 ± 59.89</td><td rowspan="1" colspan="1">0.824</td></tr><tr><td rowspan="1" colspan="1">Sleep onset latency (min)</td><td rowspan="1" colspan="1">15.53 ± 3.03</td><td rowspan="1" colspan="1">15.09 ± 2.51</td><td rowspan="1" colspan="1">14.89 ± 3.24</td><td rowspan="1" colspan="1">13.75 ± 4.02</td><td rowspan="1" colspan="1">0.187</td></tr><tr><td rowspan="1" colspan="1">Sleep Efficiency (%)</td><td rowspan="1" colspan="1">76.43 ± 7.92</td><td rowspan="1" colspan="1">71.13 ± 13.96</td><td rowspan="1" colspan="1">62.55 ± 18.09</td><td rowspan="1" colspan="1">64.42 ± 18.50</td><td align="center" rowspan="1" colspan="1">0.002 <sup>b</sup></td></tr><tr><td rowspan="1" colspan="1"> Stage N1 (%)</td><td rowspan="1" colspan="1">4.42 ± 1.24</td><td rowspan="1" colspan="1">26.22 ± 6.23</td><td rowspan="1" colspan="1">27.32 ± 5.83</td><td rowspan="1" colspan="1">32.67 ± 8.00</td><td rowspan="1" colspan="1">&lt; 0.001<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1"> Stage N2 (%)</td><td rowspan="1" colspan="1">50.47 ± 6.97</td><td rowspan="1" colspan="1">46.65 ± 9.73</td><td rowspan="1" colspan="1">54.12 ± 5.32</td><td rowspan="1" colspan="1">45.76 ± 5.58</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>b</sup></td></tr><tr><td rowspan="1" colspan="1"> Stage N3 (%)</td><td rowspan="1" colspan="1">21.20 ± 5.02</td><td rowspan="1" colspan="1">11.60 ± 3.13</td><td rowspan="1" colspan="1">10.81 ± 3.06</td><td rowspan="1" colspan="1">10.05 ± 2.62</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>b</sup></td></tr><tr><td rowspan="1" colspan="1"> REM Sleep (%)</td><td rowspan="1" colspan="1">23.90 ± 8.59</td><td rowspan="1" colspan="1">15.54 ± 10.40</td><td rowspan="1" colspan="1">7.75 ± 6.74</td><td rowspan="1" colspan="1">11.53 ± 9.46</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Arousal Index</td><td rowspan="1" colspan="1">18.23 ± 7.59</td><td rowspan="1" colspan="1">21.47 ± 11.06</td><td rowspan="1" colspan="1">25.97 ± 11.27</td><td rowspan="1" colspan="1">44.17± 21.59</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">AHI (events/h)</td><td rowspan="1" colspan="1">1. 62 ± 1.29</td><td rowspan="1" colspan="1">9.17 ± 2.83</td><td rowspan="1" colspan="1">21.28 ± 4.68</td><td rowspan="1" colspan="1">53.89 ± 13.86</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Mean SaO<sub>2</sub> (%)</td><td rowspan="1" colspan="1">95.83 ± 1.76</td><td rowspan="1" colspan="1">95.03 ± 1.50</td><td rowspan="1" colspan="1">93.83 ±1.86</td><td rowspan="1" colspan="1">90.90 ± 4.67</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Minimum SaO<sub>2</sub> (%)</td><td rowspan="1" colspan="1">87.90 ± 5.36</td><td rowspan="1" colspan="1">86.30 ± 6.09</td><td rowspan="1" colspan="1">80.40 ± 9.84</td><td rowspan="1" colspan="1">73.13 ± 13.09</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>b</sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><citation_analysis attribute="positive"><bold>Note</bold></citation_analysis><citation_analysis attribute="neither">: </citation_analysis><citation_analysis attribute="positive"><sup>b</sup></citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> value &lt; 0.05 (statistically different).</citation_analysis></p></fn><fn id="tfn0004"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="neither">: REM, rapid eye movement; Stage N1, stage 1 non-REM; Stage N2, stage 2 non-REM; Stage N3, stage 3 non-REM; AHI, Apnea-hypopnea index; SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, arterial oxygen saturation.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis></p>
      </sec>
      <sec id="s0003-s2002">
        <title>Comparison of ApoB-100, FN and CP Serum Levels in All Groups</title>
        <p><citation_analysis attribute="neither">ApoB-100, FN, and CP serum levels in patients with mild, moderate, and severe OSAHS were significantly higher than those in the control group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), and ApoB-100, FN, and CP serum levels declined gradually with the severity of OSAHS (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><xref rid="f0001" ref-type="fig">Figure 1</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p><citation_analysis attribute="neither">Comparison of ApoB-100, FN and CP serum levels in mild, moderate, severe OSAHS and controls. *Indicate statistically different (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05).</citation_analysis></p></caption><graphic xlink:href="NSS-13-2019-g0001" content-type="print-only" position="float"/></fig></citation_analysis></p>
      </sec>
      <sec id="s0003-s2003">
        <title>Comparison of dCA Parameters in All Groups</title>
        <p><citation_analysis attribute="positive">There were no significant differences between the right and left dCA parameters (PD) between groups. Therefore, average values were used in the subsequent analysis. The average PD of patients in the moderate OSAHS group (39.05 ± 10.97°) and severe OSAHS group (31.14 ± 17.45°) were lower than that of the control group (52.37 ± 9.39°, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.001, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001) or mild OSAHS group (48.22 ± 12.27°, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.041, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001) (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><xref rid="f0002" ref-type="fig">Figure 2</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p><citation_analysis attribute="neither">The autoregulatory parameter and statistical distributions in each group. Statistical distributions of average phase difference (</citation_analysis><citation_analysis attribute="positive"><bold>A</bold></citation_analysis><citation_analysis attribute="neither">) and its transfer function (</citation_analysis><citation_analysis attribute="positive"><bold>B</bold></citation_analysis><citation_analysis attribute="neither">) in each group. *Difference of average phase difference in moderate, severe OSAHS group and control group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05). </citation_analysis><citation_analysis attribute="positive"><sup>#</sup></citation_analysis><citation_analysis attribute="neither">Difference of average phase difference in moderate, severe OSAHS group and mild OSAHS group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05). Dashed frame represent specific frequency domain (0.06–0.21Hz).</citation_analysis></p></caption><graphic xlink:href="NSS-13-2019-g0002" content-type="print-only" position="float"/></fig></citation_analysis></p>
      </sec>
      <sec id="s0003-s2004">
        <title>Discriminative Power of ApoB-100, FN, and CP Serum Values to Distinguish Between OSAHS and Non-OSAHS</title>
        <p><citation_analysis attribute="neither">In the ROC analysis, the areas under the curve (AUCs) of ApoB-100, FN, and CP were 0.959 (95% confidence interval [CI]: 0.92 to 1.00, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), 0.987 (95% CI: 0.96 to 1.01, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), and 0.982 (95% CI: 0.96 to 1.00, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), respectively. The optimal cutoff value for ApoB-100 was 0.594 g/L (sensitivity, 95.6%; specificity, 96.7%), 0.735 g/L for FN (sensitivity, 96.7%; specificity, 100.0%), and 0.731 g/L for CP (sensitivity, 94.4%; specificity, 96.7%) (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0003" ref-type="fig">Figure 3</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0003" fig-type="figure"><label>Figure 3</label><caption><p><citation_analysis attribute="neither">Receiver operating characteristic (ROC) curve for apoB-100 (</citation_analysis><citation_analysis attribute="positive"><bold>A</bold></citation_analysis><citation_analysis attribute="neither">), FN (</citation_analysis><citation_analysis attribute="positive"><bold>B</bold></citation_analysis><citation_analysis attribute="neither">), and CP (</citation_analysis><citation_analysis attribute="positive"><bold>C</bold></citation_analysis><citation_analysis attribute="neither">) of OSAHS. Each panel shows the area under the curve (AUC), cutoff value, sensitivity, and specificity values.</citation_analysis></p></caption><graphic xlink:href="NSS-13-2019-g0003" content-type="print-only" position="float"/></fig></citation_analysis></p>
      </sec>
      <sec id="s0003-s2005">
        <title>Correlation Analysis for ESS, Sleep Latency, and ApoB-100, FN, and CP Serum Levels in OSAHS</title>
        <p><citation_analysis attribute="neither">In the Spearman correlation analysis, the ESS in patients with OSAHS was weakly correlated with ApoB-100 (r = - 0.231, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.028), FN (r = 0.310, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.003), and CP (r = 0.263, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P =</italic></citation_analysis><citation_analysis attribute="neither"> 0.012). Sleep latency in patients with OSAHS was not correlated with ApoB-100 (r = 0.026, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.808), FN (r = 0.151, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.155), or CP (r = 0.037, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.727).</citation_analysis></p>
      </sec>
      <sec id="s0003-s2006">
        <title>Correlation Analysis for Average PD and ApoB-100, FN, and CP Serum Levels in OSAHS</title>
        <p><citation_analysis attribute="neither">In the Spearman correlation analysis, the average PD values in patients with OSAHS were positively correlated with ApoB-100 (r = 0.695, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), FN (r = 0.850, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), and CP (r = 0.792, </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001) (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0004" ref-type="fig">Figure 4</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0004" fig-type="figure"><label>Figure 4</label><caption><p><citation_analysis attribute="neither">Relations between average phase difference and the serum levels of apoB-100 (</citation_analysis><citation_analysis attribute="positive"><bold>A</bold></citation_analysis><citation_analysis attribute="neither">), FN (</citation_analysis><citation_analysis attribute="positive"><bold>B</bold></citation_analysis><citation_analysis attribute="neither">), and CP (</citation_analysis><citation_analysis attribute="positive"><bold>C</bold></citation_analysis><citation_analysis attribute="neither">).</citation_analysis></p></caption><graphic xlink:href="NSS-13-2019-g0004" content-type="print-only" position="float"/></fig></citation_analysis></p>
      </sec>
      <sec id="s0003-s2007">
        <title>Univariable and Multivariable Analysis for Factors Affecting dCA</title>
        <p><citation_analysis attribute="neither">The clinical parameters used in the univariate and multivariate analyses are presented in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0003" ref-type="table">Table 3</xref></citation_analysis><citation_analysis attribute="neither">. In the univariable model, average PD was correlated with ApoB-100 (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), FN (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), CP (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), SL (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.032), stage N1 (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.022), arousal index (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), AHI (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), mean SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither"> (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001), and minimum SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither"> (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001).</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0003"><label>Table 3</label><caption><p><citation_analysis attribute="neither">Univariable and Multivariable Analysis for the Average Phase Difference</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Factors</th><th colspan="6" rowspan="1">Average Phase Difference, Degree</th></tr><tr><th colspan="3" rowspan="1">Univariable Analysis</th><th colspan="3" rowspan="1">Multivariable Analysis</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">β</th><th rowspan="1" colspan="1">P</th><th rowspan="1" colspan="1">R<sup>2</sup></th><th rowspan="1" colspan="1">β</th><th rowspan="1" colspan="1">P</th><th rowspan="1" colspan="1">R<sup>2</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1">− 0.159</td><td rowspan="1" colspan="1">0.135</td><td rowspan="1" colspan="1">0.025</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Age</td><td rowspan="1" colspan="1">− 0.112</td><td rowspan="1" colspan="1">0.293</td><td rowspan="1" colspan="1">0.013</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> BMI</td><td rowspan="1" colspan="1">− 0.145</td><td rowspan="1" colspan="1">0.174</td><td rowspan="1" colspan="1">0.021</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> MAP</td><td rowspan="1" colspan="1">− 0.026</td><td rowspan="1" colspan="1">0.807</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Heart Rate</td><td rowspan="1" colspan="1">− 0.156</td><td rowspan="1" colspan="1">0.141</td><td rowspan="1" colspan="1">0.024</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">− 0.133</td><td rowspan="1" colspan="1">0.211</td><td rowspan="1" colspan="1">0.018</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Hyperlipidemia</td><td rowspan="1" colspan="1">− 0.146</td><td rowspan="1" colspan="1">0.169</td><td rowspan="1" colspan="1">0.021</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">End-tidal CO2</td><td rowspan="1" colspan="1">− 0.026</td><td rowspan="1" colspan="1">0.804</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">ApoB-100</td><td rowspan="1" colspan="1">0.707</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>ab</sup></td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">0.099</td><td rowspan="1" colspan="1">0.382</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> FN</td><td rowspan="1" colspan="1">0.800</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>ab</sup></td><td rowspan="1" colspan="1">0.640</td><td rowspan="1" colspan="1">0.732</td><td rowspan="1" colspan="1">&lt; 0.001<sup>c</sup></td><td rowspan="1" colspan="1">0.660</td></tr><tr><td rowspan="1" colspan="1"> CP</td><td rowspan="1" colspan="1">0.758</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>ab</sup></td><td rowspan="1" colspan="1">0.575</td><td rowspan="1" colspan="1">0.175</td><td rowspan="1" colspan="1">0.207</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total Sleep Time (min)</td><td rowspan="1" colspan="1">0.022</td><td rowspan="1" colspan="1">0.838</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Sleep onset latency (min)</td><td rowspan="1" colspan="1">0.152</td><td rowspan="1" colspan="1">0.152</td><td rowspan="1" colspan="1">0.023</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sleep Efficiency (%)</td><td rowspan="1" colspan="1">0.226</td><td align="center" rowspan="1" colspan="1">0.032 <sup>ab</sup></td><td rowspan="1" colspan="1">0.051</td><td rowspan="1" colspan="1">0.021</td><td rowspan="1" colspan="1">0.747</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Stage N1 (%)</td><td rowspan="1" colspan="1">− 0.242</td><td align="center" rowspan="1" colspan="1">0.022 <sup>ab</sup></td><td rowspan="1" colspan="1">0.058</td><td rowspan="1" colspan="1">− 0.010</td><td rowspan="1" colspan="1">0.876</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Stage N2 (%)</td><td rowspan="1" colspan="1">0.079</td><td rowspan="1" colspan="1">0.461</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Stage N3 (%)</td><td rowspan="1" colspan="1">0.072</td><td rowspan="1" colspan="1">0.498</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> REM Sleep (%)</td><td rowspan="1" colspan="1">0.096</td><td rowspan="1" colspan="1">0.370</td><td rowspan="1" colspan="1">0.009</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Arousal Index</td><td rowspan="1" colspan="1">− 0.471</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>ab</sup></td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">− 0.158</td><td align="center" rowspan="1" colspan="1">0.025 <sup>c</sup></td><td rowspan="1" colspan="1">0.660</td></tr><tr><td rowspan="1" colspan="1">AHI (events/h)</td><td rowspan="1" colspan="1">− 0.541</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>ab</sup></td><td rowspan="1" colspan="1">0.292</td><td rowspan="1" colspan="1">0.028</td><td rowspan="1" colspan="1">0.799</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean SaO<sub>2</sub> (%)</td><td rowspan="1" colspan="1">0.438</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>ab</sup></td><td rowspan="1" colspan="1">0.192</td><td rowspan="1" colspan="1">0.108</td><td rowspan="1" colspan="1">0.141</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Minimum SaO<sub>2</sub> (%)</td><td rowspan="1" colspan="1">0.474</td><td rowspan="1" colspan="1">&lt; 0.001 <sup>ab</sup></td><td rowspan="1" colspan="1">0.225</td><td rowspan="1" colspan="1">0.084</td><td rowspan="1" colspan="1">0.254</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p><citation_analysis attribute="positive"><bold>Notes</bold></citation_analysis><citation_analysis attribute="neither">: </citation_analysis><citation_analysis attribute="positive"><sup>a</sup></citation_analysis><citation_analysis attribute="positive">Nominally significant values (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="positive"> &lt; 0.1) included in the multivariable model; </citation_analysis><citation_analysis attribute="positive"><sup>b</sup></citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> value &lt; 0.05 (statistically different); </citation_analysis><citation_analysis attribute="positive"><sup>c</sup></citation_analysis><citation_analysis attribute="neither"> Associated with average phase difference.</citation_analysis></p></fn><fn id="tfn0006"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="neither">: BMI, body mass index; MAP, mean arterial pressure; ApoB-100, apolipoprotein B-100; FN, fibronectin; CP, ceruloplasmin; REM, rapid eye movement; Stage N1, stage 1 non-REM; Stage N2, stage 2 non-REM; Stage N3, stage 3 non-REM; AHI, apnea-hypopnea index.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis></p>
        <p><citation_analysis attribute="neither">The clinical parameters with </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> ≤ 0.1 in the univariable analysis (ApoB-100, FN, CP, SL, stage N1, arousal index, AHI, mean SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, and minimum SaO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="positive">) were included in the multivariable model. FN (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001) and arousal index (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.025) were independently associated with impaired average PD.</citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0004">
      <title>Discussion</title>
      <p><citation_analysis attribute="neither">This study found that serum levels of ApoB-100, FN, and CP increased in patients with OSAHS. dCA was compromised in patients with OSAHS and was positively correlated with ApoB-100, FN, and CP serum levels, and FN serum levels and arousal index in polysomnography were independently associated with impaired dCA.</citation_analysis></p>
      <p><citation_analysis attribute="negative">Obstructive sleep apnea (OSA) is a highly prevalent medical condition that remains underdiagnosed. The American Academy of Sleep Medicine reports that blood biomarkers may be useful in identifying individuals at risk for OSA.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis><citation_analysis attribute="neither"> Fleming et al found that concurrent elevations of glycated hemoglobin (HbA1c), C-reactive protein (CRP), and erythropoietin (EPO) levels may be useful as an OSA screening tool and correlate with OSA severity.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0022" ref-type="bibr">22</xref></citation_analysis><citation_analysis attribute="positive"> Li et al suggested that patients with OSA, particularly moderate-severe OSA and those with BMI ≥  30, are significantly more likely to have elevated levels of CRP/high-sensitivity CRP.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="neither"> Gabryelska et al described that serum hypoxia-inducible factor 1 (HIF‑1α) was increased in OSA patients,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0024" ref-type="bibr">24</xref></citation_analysis><citation_analysis attribute="neither"> which was caused by intermittent nocturnal hypoxia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis><citation_analysis attribute="positive"> Furthermore, single-night continuous positive airway pressure (CPAP) therapy seems to be insufficient to affect the increased level of the protein.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0026" ref-type="bibr">26</xref></citation_analysis><citation_analysis attribute="neither"> Lu et al observed decreased levels of HIF-1α following 2 months of CPAP treatment compared to baseline results.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0027" ref-type="bibr">27</xref></citation_analysis><citation_analysis attribute="positive"> Many previous studies have shown that OSAHS is associated with dyslipidemia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0028" ref-type="bibr">28–30</xref></citation_analysis><citation_analysis attribute="neither"> The abnormal metabolism of ApoB-100 is an important component of dyslipidemia and is dynamically related to overproduction of very low-density lipoprotein (VLDL) and ApoB-100, decreased catabolism of apolipoprotein B particles, and accelerated catabolism of high-density lipoprotein (HDL) particles.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither"> The utilization of lipids could affect the metabolic pool of intercellular ApoB-100. Chronic intermittent hypoxia can cause metabolic dysfunction and abnormal lipid metabolism, leading to decreased utilization of lipids and an increase in plasma levels. FN is a protein marker for the activation of endothelial cells.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither"> The mechanism of increased FN serum levels in patients with OSAHS is that hypoxia increases FN synthesis at the transcriptional level and promotes the secretion of FN into the extracellular fluid.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="neither"> A study has found that the main degradation enzymes of FN, including matrix metallopeptidase-2 and matrix metallopeptidase-9, are increased in patients with OSAHS,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> which indicates that the increase in extracellular FN is not caused by a decrease in degradation and suggests that hypoxia could promote the synthesis and secretion of FN in myofibroblasts. In patients with OSAHS, glycolipid shedding on the cell surface increases because of acute inflammation, which leads to an abnormal increase of sialic acid in blood. Activated sialyltransferase degrades and desialylates CP, thus affecting its normal degradation process and resulting in an increase in the serum level of CP.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0013" ref-type="bibr">13</xref></citation_analysis><citation_analysis attribute="positive"> We are studying some inflammatory factors, including immunoglobulin λ light chain (λ-IgLC), filaggrin (FLG), transthyretin (TTR) and will further add them in the follow-up study.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Some studies have shown that changes in these serum markers show an upward trend with the gradual aggravation of the severity of OSAHS,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="neither"> but not all of them. Gamez et al found that antithrombin and thrombin sensitizing protein-1 serum levels decreased in the moderate group and thrombin sensitizing protein-1 decreased in the severe group with low protein expression. CP serum levels increased in the moderate group and decreased significantly in the severe group.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither"> There was also incomplete aggravation in our research results; ApoB-100, FN, and CP serum levels declined gradually with the severity of OSAHS. This may reflect abnormal protein synthesis, transportation, and ubiquitination in severe or chronic OSAHS, resulting in the decline of protein function and serum levels. It may also be that when the damage from hypoxia reaches a certain degree, it does not continue, and the body gradually employs a compensatory protective mechanism to eliminate the damage so that the inflammatory-related proteins gradually decrease in serum.</citation_analysis></p>
      <p><citation_analysis attribute="positive">The mechanism of impaired dCA in patients with OSAHS involves endothelial, metabolic, myogenic, and neurogenic theories. Carlson et al reported for the first time that the ability of acetylcholine-induced vasodilation (endothelium-dependent response) in patients with OSAHS decreased compared with age- and BMI-matched subjects.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis><citation_analysis attribute="neither"> Endothelial dysfunction is of great significance to vasomotor function.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="neither"> ApoB-100 is the main carrier of LDL, which plays an important role in the transport of endogenous cholesterol and triglycerides as well as LDL metabolism.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis><citation_analysis attribute="neither"> It has a strong stimulating effect on the esterification of cholesterol in macrophages, which can promote the formation of foam cells, affect endothelial function, and lead to arteriosclerosis</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37</xref></citation_analysis><citation_analysis attribute="neither"> and affect dCA. FN is a medium connection between cells and stroma, participating in the promotion of cell adhesion and activation of macrophages, and is closely related to the process of angiogenesis, inflammation, tissue fibrosis, and autoregulation.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0014" ref-type="bibr">14</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="neither"> CP is an acute inflammatory response protein, which could cause Cu</citation_analysis><citation_analysis attribute="positive"><sup>2+</sup></citation_analysis><citation_analysis attribute="neither"> to abscise and lead to oxidative modification of LDL in certain circumstances; it can also cause endothelial injury and activate monocyte-releasing factor, leading to the formation and migration of foam cells, the proliferation of vascular smooth muscle cells, and the atherosclerosis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="neither"> Our study showed that impaired dCA was positively correlated with ApoB-100, FN, and CP serum levels in patients with moderate and severe OSAHS.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Repeated hypoventilation, apnea, and frequent awakening may affect the autonomic nervous system. Long-term hypoxemia in patients with OSAHS can activate chemoreceptors in the carotid body and increase sympathetic vasoconstriction, leading to decreased cerebral blood flow. Hypercapnia stimulates central chemoreceptors in the brainstem and increases sympathetic nerve tension through a similar process. At the same time, the negative pressure in the thoracic cavity increases, which inhibits the afferent activity of the autonomic nervous system in the pulmonary system, stimulates baroreceptors, causes vasoconstriction,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither"> and affects dCA.</citation_analysis></p>
      <p><citation_analysis attribute="neither">This study has several limitations. First, we did not examine the dCA and serum levels of ApoB-100, FN, and CP after standard treatment. Second, the sample size of this study was small, which may have limited the analysis. Further work is required to explore other serological markers of OSAHS and to study their relationship with dCA, providing a basis for clinical diagnosis and treatment.</citation_analysis></p>
    </sec>
    <sec id="s0005">
      <title>Conclusions</title>
      <p><citation_analysis attribute="neither">Serum levels of ApoB-100, FN, and CP increased in patients with OSAHS. dCA was compromised in patients with OSAHS and was positively correlated with ApoB-100, FN, and CP serum levels, and FN serum levels and arousal index in polysomnography were independently associated with impaired dCA.</citation_analysis></p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p><citation_analysis attribute="neither">The authors would like to acknowledge the following individual at Jilin University: Chunhui Wei for their technical support and Qiong Yu for the statistical analysis. Yanan Zhang and Xiaodan Wu are the co-first author.</citation_analysis></p>
    </ack>
    <sec id="s0006">
      <title>Data Sharing Statement</title>
      <p><citation_analysis attribute="positive">The data that support the findings of this study will be made available on request.</citation_analysis></p>
    </sec>
    <sec sec-type="COI-statement" id="s0007">
      <title>Disclosure</title>
      <p><citation_analysis attribute="neither">The authors declare no conflicts of interest for this work.</citation_analysis></p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Yaggi</surname>
<given-names>HK</given-names></string-name>, <string-name><surname>Concato</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kernan</surname>
<given-names>WN</given-names></string-name>, <string-name><surname>Lichtman</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Brass</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Mohsenin</surname>
<given-names>V</given-names></string-name>. <article-title>Obstructive sleep apnea as a risk factor for stroke and death</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2005</year>;<volume>353</volume>(<issue>19</issue>):<fpage>2034</fpage>–<lpage>2041</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa043104</pub-id><pub-id pub-id-type="pmid">16282178</pub-id></mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ryan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Taylor</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>McNicholas</surname>
<given-names>WT</given-names></string-name>. <article-title>Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome</article-title>. <source><italic toggle="yes">Circulation</italic></source>. <year>2005</year>;<volume>112</volume>(<issue>17</issue>):<fpage>2660</fpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.556746</pub-id><pub-id pub-id-type="pmid">16246965</pub-id></mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lavie</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lavie</surname>
<given-names>P</given-names></string-name>. <article-title>Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2009</year>;<volume>33</volume>(<issue>6</issue>):<fpage>1467</fpage>–<lpage>1484</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00086608</pub-id><pub-id pub-id-type="pmid">19483049</pub-id></mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jelic</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Padeletti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kawut</surname>
<given-names>SM</given-names></string-name>, et al. <article-title>Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea</article-title>. <source><italic toggle="yes">Circulation</italic></source>. <year>2008</year>;<volume>117</volume>(<issue>17</issue>):<fpage>2270</fpage>–<lpage>2278</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.741512</pub-id><pub-id pub-id-type="pmid">18413499</pub-id></mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tanno</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tanigawa</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Saito</surname>
<given-names>I</given-names></string-name>, et al. <article-title>Sleep-related intermittent hypoxemia and glucose intolerance: a community-based study</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>10</issue>):<fpage>1212</fpage>–<lpage>1218</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.05.027</pub-id><pub-id pub-id-type="pmid">25156748</pub-id></mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nasr</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Traon</surname>
<given-names>AP</given-names></string-name>, <string-name><surname>Czosnyka</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tiberge</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Schmidt</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Larrue</surname>
<given-names>V</given-names></string-name>. <article-title>Cerebral autoregulation in patients with obstructive sleep apnea syndrome during wakefulness</article-title>. <source><italic toggle="yes">Eur J Neurol</italic></source>. <year>2009</year>;<volume>16</volume>(<issue>3</issue>):<fpage>386</fpage>–<lpage>391</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02505.x</pub-id><pub-id pub-id-type="pmid">19175381</pub-id></mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Claassen</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Meel-van den Abeelen</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Simpson</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Panerai</surname>
<given-names>RB</given-names></string-name>; <collab>International Cerebral Autoregulation Research Network (CARNet)</collab>. <article-title>Transfer function analysis of dynamic cerebral autoregulation: a white paper from the International Cerebral Autoregulation Research Network</article-title>. <source><italic toggle="yes">J Cereb Blood Flow Metab</italic></source>. <year>2016</year>;<volume>36</volume>(<issue>4</issue>):<fpage>665</fpage>–<lpage>680</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0271678X15626425</pub-id><pub-id pub-id-type="pmid">26782760</pub-id></mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hamel</surname>
<given-names>E</given-names></string-name>. <article-title>Perivascular nerves and the regulation of cerebrovascular tone</article-title>. <source><italic toggle="yes">J Appl Physiol</italic></source>. <year>2006</year>;<volume>100</volume>(<issue>3</issue>):<fpage>1059</fpage>–<lpage>1064</lpage>. doi:<pub-id pub-id-type="doi">10.1152/japplphysiol.00954.2005</pub-id><pub-id pub-id-type="pmid">16467392</pub-id></mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Madani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Madani</surname>
<given-names>F</given-names></string-name>. <article-title>Epidemiology, pathophysiology, and clinical features of obstructive sleep apnea</article-title>. <source><italic toggle="yes">Oral Maxillofac Surg Clin North Am</italic></source>. <year>2009</year>;<volume>21</volume>(<issue>4</issue>):<fpage>369</fpage>–<lpage>735</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.coms.2009.09.003</pub-id><pub-id pub-id-type="pmid">19944337</pub-id></mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gabryelska</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Szmyd</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Panek</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Szemraj</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kuna</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Białasiewicz</surname>
<given-names>P</given-names></string-name>. <article-title>Serum hypoxia-inducible factor-1α protein level as a diagnostic marker of obstructive sleep apnea</article-title>. <source><italic toggle="yes">Pol Arch Intern Med</italic></source>. <year>2020</year>;<volume>130</volume>(<issue>2</issue>):<fpage>158</fpage>–<lpage>160</lpage>. doi:<pub-id pub-id-type="doi">10.20452/pamw.15104</pub-id><pub-id pub-id-type="pmid">31834288</pub-id></mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hennig</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Chow</surname>
<given-names>CK</given-names></string-name>. <article-title>Lipid peroxidation and endothelial cell injury: implications in atherosclerosis</article-title>. <source><italic toggle="yes">Free Radic Biol Med</italic></source>. <year>1988</year>;<volume>4</volume>(<issue>2</issue>):<fpage>99</fpage>–<lpage>106</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0891-5849(88)90070-6</pub-id><pub-id pub-id-type="pmid">3278952</pub-id></mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>The contribution of chronic intermittent hypoxia to OSAHS: from the perspective of serum extracellular microvesicle proteins</article-title>. <source><italic toggle="yes">Metabolism</italic></source>. <year>2018</year>;<volume>85</volume>:<fpage>97</fpage>–<lpage>108</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.metabol.2018.02.012</pub-id><pub-id pub-id-type="pmid">29522771</pub-id></mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cox</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Teknos</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>Barrios</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Brewer</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Dick</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Merajver</surname>
<given-names>SD</given-names></string-name>. <article-title>The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma</article-title>. <source><italic toggle="yes">Laryngoscope</italic></source>. <year>2001</year>;<volume>111</volume>(<issue>4 Pt 1</issue>):<fpage>696</fpage>–<lpage>701</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00005537-200104000-00024</pub-id><pub-id pub-id-type="pmid">11359142</pub-id></mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wijelath</surname>
<given-names>ES</given-names></string-name>, <string-name><surname>Rahman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Murray</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Patel</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Savidge</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Sobel</surname>
<given-names>M</given-names></string-name>. <article-title>Fibronectin promotes VEGF-induced CD34 cell differentiation into endothelial cells</article-title>. <source><italic toggle="yes">J Vasc Surg</italic></source>. <year>2004</year>;<volume>39</volume>(<issue>3</issue>):<fpage>655</fpage>–<lpage>660</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jvs.2003.10.042</pub-id><pub-id pub-id-type="pmid">14981463</pub-id></mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Engström</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Lind</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Hedblad</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Stavenow</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Janzon</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lindgärde</surname>
<given-names>F</given-names></string-name>. <article-title>Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men</article-title>. <source><italic toggle="yes">Circulation</italic></source>. <year>2002</year>;<volume>105</volume>(<issue>22</issue>):<fpage>2632</fpage>–<lpage>2637</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.cir.0000017327.69909.ff</pub-id><pub-id pub-id-type="pmid">12045169</pub-id></mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Feliciano</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Torres</surname>
<given-names>VM</given-names></string-name>, <string-name><surname>Vaz</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Overview of proteomics studies in obstructive sleep apnea</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2015</year>;<volume>16</volume>(<issue>4</issue>):<fpage>437</fpage>–<lpage>445</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.11.014</pub-id><pub-id pub-id-type="pmid">25770042</pub-id></mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lv</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>ZN</given-names></string-name>, <string-name><surname>Jin</surname>
<given-names>H</given-names></string-name>, et al. <article-title>Compromised dynamic cerebral autoregulation in patients with epilepsy</article-title>. <source><italic toggle="yes">Biomed Res Int</italic></source>. <year>2018</year>;<volume>2018</volume>:<fpage>6958476</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2018/6958476</pub-id>.<pub-id pub-id-type="pmid">29568762</pub-id></mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Luo</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>ZN</given-names></string-name>, <string-name><surname>Qu</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Compromised dynamic cerebral autoregulation in patients with depression</article-title>. <source><italic toggle="yes">Front Psychiatry</italic></source>. <year>2019</year>;<volume>10</volume>:<fpage>373</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2019.00373</pub-id><pub-id pub-id-type="pmid">31258489</pub-id></mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>van Beek</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Claassen</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Rikkert</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Jansen</surname>
<given-names>RW</given-names></string-name>. <article-title>Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly</article-title>. <source><italic toggle="yes">J Cereb Blood Flow Metab</italic></source>. <year>2008</year>;<volume>28</volume>(<issue>6</issue>):<fpage>1071</fpage>–<lpage>1085</lpage>. doi:<pub-id pub-id-type="doi">10.1038/jcbfm.2008.13</pub-id><pub-id pub-id-type="pmid">18349877</pub-id></mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kuo</surname>
<given-names>TB</given-names></string-name>, <string-name><surname>Chern</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Sheng</surname>
<given-names>WY</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>HH</given-names></string-name>. <article-title>Frequency domain analysis of cerebral blood flow velocity and its correlation with arterial blood pressure</article-title>. <source><italic toggle="yes">J Cereb Blood Flow Metab</italic></source>. <year>1998</year>;<volume>18</volume>(<issue>3</issue>):<fpage>311</fpage>–<lpage>318</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00004647-199803000-00010</pub-id><pub-id pub-id-type="pmid">9498848</pub-id></mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kapur</surname>
<given-names>VK</given-names></string-name>, <string-name><surname>Auckley</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Chowdhuri</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2017</year>;<volume>13</volume>(<issue>3</issue>):<fpage>479</fpage>–<lpage>504</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.6506</pub-id><pub-id pub-id-type="pmid">28162150</pub-id></mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fleming</surname>
<given-names>WE</given-names></string-name>, <string-name><surname>Holty</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Bogan</surname>
<given-names>RK</given-names></string-name>, et al. <article-title>Use of blood biomarkers to screen for obstructive sleep apnea</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2018</year>;<volume>10</volume>:<fpage>159</fpage>–<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.2147/NSS.S164488</pub-id><pub-id pub-id-type="pmid">29942168</pub-id></mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Qin</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>Y</given-names></string-name>. <article-title>Is C-reactive protein a marker of obstructive sleep apnea?: a meta-analysis</article-title>. <source><italic toggle="yes">Medicine</italic></source>. <year>2017</year>;<volume>96</volume>(<issue>19</issue>):<fpage>e6850</fpage>. doi:<pub-id pub-id-type="doi">10.1097/MD.0000000000006850</pub-id><pub-id pub-id-type="pmid">28489776</pub-id></mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gabryelska</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Karuga</surname>
<given-names>FF</given-names></string-name>, <string-name><surname>Szmyd</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Białasiewicz</surname>
<given-names>P</given-names></string-name>. <article-title>HIF-1α as a mediator of insulin resistance, T2DM, and its complications: potential links with obstructive sleep apnea</article-title>. <source><italic toggle="yes">Front Physiol</italic></source>. <year>2020</year>;<volume>11</volume>:<fpage>1035</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphys.2020.01035</pub-id><pub-id pub-id-type="pmid">33013447</pub-id></mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gabryelska</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Szmyd</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Szemraj</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Stawski</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sochal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Białasiewicz</surname>
<given-names>P</given-names></string-name>. <article-title>Patients with obstructive sleep apnea present with chronic upregulation of serum HIF-1α protein</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1761</fpage>–<lpage>1768</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.8682</pub-id><pub-id pub-id-type="pmid">32663129</pub-id></mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gabryelska</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Stawski</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sochal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Szmyd</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Białasiewicz</surname>
<given-names>P</given-names></string-name>. <article-title>Influence of one-night CPAP therapy on the changes of HIF-1α protein in OSA patients: a pilot study</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2020</year>;<volume>29</volume>(<issue>4</issue>):<fpage>e12995</fpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.12995</pub-id><pub-id pub-id-type="pmid">32166825</pub-id></mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>L</given-names></string-name>. <article-title>Potential inflammatory markers in obstructive sleep apnea-hypopnea syndrome</article-title>. <source><italic toggle="yes">Bosn J Basic Med Sci</italic></source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>47</fpage>–<lpage>53</lpage>. doi:<pub-id pub-id-type="doi">10.17305/bjbms.2016.1579</pub-id><pub-id pub-id-type="pmid">27754829</pub-id></mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McArdle</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hillman</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Beilin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Watts</surname>
<given-names>G</given-names></string-name>. <article-title>Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med</italic></source>. <year>2007</year>;<volume>175</volume>(<issue>2</issue>):<fpage>190</fpage>–<lpage>195</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.200602-270OC</pub-id><pub-id pub-id-type="pmid">17068329</pub-id></mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Newman</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Nieto</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Guidry</surname>
<given-names>U</given-names></string-name>, et al.; <collab>Sleep Herat Health Study Research Group</collab>. <article-title>Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study</article-title>. <source><italic toggle="yes">Am Epidemiol</italic></source>. <year>2001</year>;<volume>154</volume>(<issue>1</issue>):<fpage>50</fpage>–<lpage>59</lpage>. doi:<pub-id pub-id-type="doi">10.1093/aje/154.1.50</pub-id></mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Drager</surname>
<given-names>LF</given-names></string-name>, <string-name><surname>Jun</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Polotsky</surname>
<given-names>VY</given-names></string-name>. <article-title>Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis</article-title>. <source><italic toggle="yes">Curr Opin Endocrinol Diabetes Obes</italic></source>. <year>2010</year>;<volume>17</volume>(<issue>2</issue>):<fpage>161</fpage>–<lpage>165</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MED.0b013e3283373624</pub-id><pub-id pub-id-type="pmid">20125003</pub-id></mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Watts</surname>
<given-names>GF</given-names></string-name>, <string-name><surname>Ooi</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Chan</surname>
<given-names>DC</given-names></string-name>. <article-title>Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo</article-title>. <source><italic toggle="yes">Pharmacol Ther</italic></source>. <year>2009</year>;<volume>123</volume>(<issue>3</issue>):<fpage>281</fpage>–<lpage>291</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pharmthera.2009.04.005</pub-id><pub-id pub-id-type="pmid">19490928</pub-id></mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ozcelik</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Erdogan</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Aktoz</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ekuklu</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Tatli</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Demir</surname>
<given-names>M</given-names></string-name>. <article-title>Diagnostic value of plasma fibronectin level in predicting the presence and severity of coronary artery disease</article-title>. <source><italic toggle="yes">Ann Hematol</italic></source>. <year>2009</year>;<volume>88</volume>(<issue>33</issue>):<fpage>249</fpage>–<lpage>253</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00277-008-0573-x</pub-id><pub-id pub-id-type="pmid">18716775</pub-id></mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hopps</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Canino</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Montana</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Gelatinases and their tissue inhibitors in a group of subjects with obstructive sleep apnea syndrome</article-title>. <source><italic toggle="yes">Clin Hemorheol Microcirc</italic></source>. <year>2016</year>;<volume>62</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.3233/CH-151928</pub-id><pub-id pub-id-type="pmid">25757454</pub-id></mixed-citation>
      </ref>
      <ref id="cit0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jurado-Gamez</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Gomez-Chaparro</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Muñoz-Calero</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Serum proteomic changes in adults with obstructive sleep apnoea</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2012</year>;<volume>21</volume>(<issue>2</issue>):<fpage>139</fpage>–<lpage>146</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2869.2011.00955.x</pub-id><pub-id pub-id-type="pmid">21923731</pub-id></mixed-citation>
      </ref>
      <ref id="cit0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Carlson</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Rangemark</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hedner</surname>
<given-names>JA</given-names></string-name>. <article-title>Attenuated endothelium-dependent vascular relaxation in patients with sleep apnoea</article-title>. <source><italic toggle="yes">J Hypertens</italic></source>. <year>1996</year>;<volume>14</volume>(<issue>5</issue>):<fpage>577</fpage>–<lpage>584</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00004872-199605000-00006</pub-id><pub-id pub-id-type="pmid">8762200</pub-id></mixed-citation>
      </ref>
      <ref id="cit0036">
        <label>36.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wåhlin-Larsson</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ulfberg</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Aulin</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Kadi</surname>
<given-names>F</given-names></string-name>. <article-title>The expression of vascular endothelial growth factor in skeletal muscle of patients with sleep disorders</article-title>. <source><italic toggle="yes">Muscle Nerve</italic></source>. <year>2009</year>;<volume>40</volume>(<issue>4</issue>):<fpage>556</fpage>–<lpage>561</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.21357</pub-id><pub-id pub-id-type="pmid">19623635</pub-id></mixed-citation>
      </ref>
      <ref id="cit0037">
        <label>37.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tan</surname>
<given-names>KC</given-names></string-name>, <string-name><surname>Chow</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Lam</surname>
<given-names>JC</given-names></string-name>, et al. <article-title>HDL dysfunction in obstructive sleep apnea</article-title>. <source><italic toggle="yes">Atherosclerosis</italic></source>. <year>2006</year>;<volume>184</volume>(<issue>2</issue>):<fpage>377</fpage>–<lpage>382</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2005.04.024</pub-id><pub-id pub-id-type="pmid">15975582</pub-id></mixed-citation>
      </ref>
      <ref id="cit0038">
        <label>38.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wijelath</surname>
<given-names>ES</given-names></string-name>, <string-name><surname>Murray</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rahman</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity</article-title>. <source><italic toggle="yes">Circ Res</italic></source>. <year>2002</year>;<volume>91</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.res.0000026420.22406.79</pub-id><pub-id pub-id-type="pmid">12114318</pub-id></mixed-citation>
      </ref>
      <ref id="cit0039">
        <label>39.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Palma</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Urrestarazu</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lopez-Azcarate</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Increased sympathetic and decreased parasympathetic cardiac tone in patients with sleep related alveolar hypoventilation</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2013</year>;<volume>36</volume>(<issue>6</issue>):<fpage>933</fpage>–<lpage>940</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.2728</pub-id><pub-id pub-id-type="pmid">23729937</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
